A Review On The Latest Developments And Breakthroughs In Ocular Drug Delivery

Not only for pharmaceutical compounds like steroids, nonsteroidal anti-inflammatory drugs, immune modulators, antibiotics, and so on, but also for the rapidly progressing gene therapy products, ocular drug delivery has made significant advancements in recent years. This is true for all of these types of medications. When it comes to conventional drugs that aren't used in gene therapy, the primary considerations that go into achieving satisfactory treatment outcomes are appropriate surgical methods and releasing systems. On the other hand, the definition of "drug delivery" for gene therapy drugs includes further considerations such as transgene construct optimization, vector selection, and vector engineering. Because of its many redeeming qualities, the eye makes for an excellent candidate for the therapeutic use of gene therapy. In this overview, we will focus on three primary elements of ocular medication delivery, discussing them in relation to both conventional pharmaceuticals and gene therapy products based on adeno-associated virus (AAV): (1) the creation of AAV vector systems for use in ocular gene therapy, (2) the development of novel carriers for medications, and (3) the evolution of methods for administering medications.